Foghorn Therapeutics (FHTX) Accumulated Expenses (2019 - 2026)

Foghorn Therapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 7.28% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (up 7.28% YoY), while the FY2025 annual figure was $11.4 million, up 33.13% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.9 million, down from $11.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $11.4 million in Q4 2025, with the low at $6.3 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $8.6 million (2025), against an average of $8.6 million.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses soared 57.14% in 2022, then fell 29.06% in 2024.
• Foghorn Therapeutics' Accumulated Expenses stood at $11.0 million in 2022, then slipped by 17.21% to $9.1 million in 2023, then retreated by 6.34% to $8.5 million in 2024, then jumped by 33.13% to $11.4 million in 2025, then slumped by 39.03% to $6.9 million in 2026.
• Business Quant data shows FHTX's Accumulated Expenses at $6.9 million in Q1 2026, $11.4 million in Q4 2025, and $9.8 million in Q3 2025.